Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3241 PET Study in Parkinson's Disease
NCT01527695Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2012
- Primary completion
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing AZD3241 with Placebo (2 arms). Primary endpoint: Change of binding [11C]PBR28 to translocator protein (TSPO). Started Apr 2012; status: completed.
02
Drugs
verdiperstat
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01527695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01527695.